- (rVSV-ZEBOV), also
known as
Ebola Zaire vaccine live and sold
under the
brand name
Ervebo, is an
Ebola vaccine for
adults that
prevents Ebola caused by the Zaire...
-
Ervebo (rVSV∆G-ZEBOV-GP, live) and the WHO
prequalified an
Ebola vaccine for the
first time. In July 2023, the FDA
expanded the
indication for
Ervebo...
- RNA-dependent RNA
polymerase proteins. The rVSV-ZEBOV vaccine,
known as
Ervebo, was
approved as a
prophylactic Ebola vaccine for
medical use by the FDA...
-
Brazilian Approval,
Zacks Equity Research, Zacks.com, 29
December 2015 "Merck's
Ervebo [Ebola
Zaire Vaccine (rVSVΔG-ZEBOV-GP) live]
Granted Conditional Approval...
- for
Biologics Evaluation and (2020-01-27). "
ERVEBO". FDA. CZARSKA-THORLEY,
Dagmara (2019-10-16). "
Ervebo".
European Medicines Agency.
Retrieved 2020-05-03...
- rVSV-ZEBOV vaccine) In
December 2019,
Merck & Co.'s rVSV-ZEBOV
vaccine Ervebo was
approved by the Food and Drug
Administration to
treat individuals 18...
-
starting in 2018),
BARDA supported the
development of the
first Ebola vaccine,
ERVEBO, by
BioProtection Systems, a
subsidiary of
NewLink Genetics Inc. (now Lumos...
-
pediatric Trikafta Cystic fibrosis Vertex Pharmaceuticals Tropical disease Ervebo Ebola Merck & Co.
Capmatinib MET exon 14
skipping mutated non-small cell...
-
vaccine results are
encouraging – but preliminary". PBS. 23
December 2016. "
Ervebo". EMA. 12
December 2019.
Retrieved 2
February 2020. "First FDA-approved...
- 2019, the
first Ebola vaccine was approved. rVSV-ZEBOV,
otherwise known as
Ervebo, is a
vaccine for
adults that
prevents the
Zaire ebolavirus. In October...
